Differences in Treatment Goals and Expectations Among Patients With Relapsed/Refractory Multiple Myeloma Treated in Academic vs Community Settings
Biru Y, Clavreul S, Rasche L, Davies R, Greenwood A, Watkins J, Farrell J, Ailawadhi S
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Socioeconomic Factors Affecting Health Equity in Patients With Relapsed or Refractory Multiple Myeloma
Efebera Y, O'Donnell J, Biru Y, Cormier N, Davies R, Greenwood A, Farrell J, Watkins J, Rasche L
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Elranatamab Fixed Dosing: The Optimal Dosing Strategy for Safety, Efficacy, and Convenience Across Body Weights
Elmeliegy M, Soltantabar P, Hibma J, Ashman O, Lon H-K
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Patient Characteristics, Healthcare Utilization and Costs in Multiple Myeloma by Treatment Class Exposure – A German Claims Data Study
Greth K, Lehne M, Mevius A, Aydin D, Gokhale M, Russell A
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
BasecaMMp: An OBservational Retrospective Analysis of Treatment PatternS and Effectiveness of Standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor
Kortüm KM, Farrell J, Zhuleku E, McDonald K, Ashman O, Nador G, Rückert M, Theurich S
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Differential Impact of BCMA (TNFRSF17) Extracellular Domain Mutations on In Vitro Potency of Elranatamab Versus Teclistamab
Josic M, Schweibold R, Chu T, Lui C, Mosyak L, Bompiani-Myers K
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Understanding Specific Treatment Sequences in Multiple Myeloma Dependent on the Treatment Received in Second Line: Survey Data From 141 International Clinicians
Richter J, Farrell J, Aydin D, Burke C, Comoroda D
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Understanding Different Treatment Goals and Experiences According to Characteristics in Relapsed/Refractory Multiple Myeloma
Popat R, Clavreul S, Greenwood A, Davies R, Farrell J, Watkins J, Ailawadhi S
IMS 2025
- 国际多发性骨髓瘤学会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
